NSMCE2

Across TCGA pan-cancer cohorts, NSMCE2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated NSMCE2 data layer compared with 26 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher NSMCE2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated NSMCE2 expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

HNSC, LSCC, and LUAD are the cancer types where NSMCE2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Quartile	III,IV	0.731	0.933	.012	15	view →
LSCC	DFS	Median	II,III,IV	1.000	0.841	.008	9	view →
LUAD	DFS	Median	III,IV	0.930	0.584	.026	9	view →
PDAC	OS	Quartile	III,IV	0.852	0.384	.040	7	view →
CCRCC	OS	Median	All	0.905	0.743	.006	5	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

NSMCE2–HNSC (OS)

Open the HNSC breakdown →